Minori's mailing address filed with the SEC is C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Sesen Bio have traded over $121,419 worth of Sesen Bio stock. The most active insiders traders include Thomas R Cannell, Monica Forbes a Mark Sullivan. On average, Sesen Bio executives and independent directors trade stock every 1 days with the average trade being worth of $111,396. The most recent stock trade was executed by Mark Sullivan on 2 March 2023, trading 298,175 units of SESN stock currently worth $175,923.
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
Sesen Bio executives and other stock owners filed with the SEC include: